These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1928082)

  • 1. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis.
    Evans RW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):62-70. PubMed ID: 1928082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and hematocrit level.
    Levin NW
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):16-20. PubMed ID: 1626552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quality of life of dialysis patients treated with recombinant human erythropoietin.
    Auer J; Oliver DO; Winearls CG
    Scand J Urol Nephrol Suppl; 1990; 131():61-5. PubMed ID: 2075472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in the era of erythropoietin.
    Weisbord SD; Kimmel PL
    Hemodial Int; 2008 Jan; 12(1):6-15. PubMed ID: 18271834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin in predialysis patients.
    Lim VS
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):34-7. PubMed ID: 1928077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
    Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
    Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on the improvement of quality of life with epoetin alfa therapy.
    Lundin AP; Delano BG; Quinn-Cefaro R
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):22S-26S. PubMed ID: 2345708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does early anemia correction prevent complications of chronic renal failure?
    Drüeke TB; Eckardt KU; Frei U; Jacobs C; Kokot F; McMahon LP; Schaefer RM
    Clin Nephrol; 1999 Jan; 51(1):1-11. PubMed ID: 9988140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quality of life of patients with end-stage renal disease.
    Evans RW; Manninen DL; Garrison LP; Hart LG; Blagg CR; Gutman RA; Hull AR; Lowrie EG
    N Engl J Med; 1985 Feb; 312(9):553-9. PubMed ID: 3918267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin treatment improves quality of life in hemodialysis patients.
    Bárány P; Pettersson E; Bergström J
    Scand J Urol Nephrol Suppl; 1990; 131():55-60. PubMed ID: 2075471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group.
    Evans RW; Rader B; Manninen DL
    JAMA; 1990 Feb; 263(6):825-30. PubMed ID: 2404150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease.
    Korbet SM
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):9-15. PubMed ID: 2648520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic occult intra-alveolar hemorrhage: a rare cause of failure to respond to erythropoietin.
    Conlon PJ; O'Neill S; O'Neill G; Kelly F; Donohoe J
    Clin Nephrol; 1994 Feb; 41(2):83-5. PubMed ID: 8004833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.